|
|
Volumn 8, Issue 10, 2011, Pages 567-
|
|
Targeted therapies: Should we be aghast at the AVAGAST data?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CISPLATIN;
FLUOROPYRIMIDINE;
PLACEBO;
ADVANCED CANCER;
ANTIANGIOGENIC THERAPY;
BREAST CANCER;
CANCER STAGING;
CANCER SURVIVAL;
COLORECTAL CANCER;
DRUG EFFICACY;
ESOPHAGEAL ADENOCARCINOMA;
GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA;
HUMAN;
LOWER ESOPHAGUS SPHINCTER;
LUNG CANCER;
METASTASIS;
NOTE;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
STOMACH ADENOCARCINOMA;
STOMACH CANCER;
|
|
EID: 80053568441
PISSN: 17594774
EISSN: 17594782
Source Type: Journal
DOI: 10.1038/nrclinonc.2011.115 Document Type: Note |
|
Times cited : (2)
|
|
References (1)
|
